Drug Sponsors

Bayer to acquire Algeta

Friday, December 20, 2013 01:41 PM

Bayer, through Aviator Acquisition, a wholly-owned subsidiary of Bayer Nordic, will launch a voluntary offer to acquire Algeta for $58.7 per share in cash, for a total value of approximately $2.9 billion. Algeta’s board of directors has unanimously decided to recommend its shareholders accept the offer.

More... »

AstraZeneca to acquire Bristol-Myers Squibb share of diabetes alliance assets

Friday, December 20, 2013 11:00 AM

AstraZeneca will acquire the entirety of Bristol-Myers Squibb's interest in the companies' diabetes alliance for $2.7 billion, and up to $1.4 billion in regulatory, launch and sales-related payments. AstraZeneca also has agreed to pay various sales-related royalty payments up until 2025 and may make payments up to $225 million when certain assets are subsequently transferred.

More... »


Endo to acquire NuPathe

Wednesday, December 18, 2013 01:44 PM

Endo Health Solutions, a U.S.-based specialty healthcare company, has entered into a definitive agreement to acquire NuPathe, a specialty pharmaceutical company focused on neuroscience solutions for central nervous system diseases, for $2.85 per share in cash, or approximately $105 million. 

More... »

Almirall to acquire Aqua Pharmaceuticals

Wednesday, December 18, 2013 01:36 PM

Almirall, an international pharmaceutical company based in Spain, has acquired Aqua Pharmaceuticals, a privately-held, U.S.-based prescription dermatology company with a portfolio of prescription brands in acne, steroid-responsive dermatoses, seborrheic dermatitis, actinic keratosis and atopic dermatitis.

More... »

Valeant Pharmaceuticals to acquire Solta Medical

Monday, December 16, 2013 02:19 PM

Valeant Pharmaceuticals International will acquire all outstanding common stock of Solta Medical for $2.92 per share in cash, for a transaction value of approximately $250 million. The transaction is expected to close in the first quarter of 2014.

More... »

Vivus, Sanofi ink agreement

Friday, December 13, 2013 01:57 PM

Biopharmaceutical company Vivus has entered into a license and commercialization agreement with Sanofi to commercialize avanafil on an exclusive basis in Africa, the Middle East, Turkey and the Commonwealth of Independent States (CIS) including Russia. Sanofi will be responsible for obtaining regulatory approval in its territories. Sanofi intends to market avanafil under the trade name Spedra or Stendra.

More... »

Johnson & Johnson Innovation establishes network of partnering offices

Monday, December 9, 2013 12:29 PM

Johnson & Johnson Innovation, London, has formed a network of partnering offices across U.K. life science clusters. The offices function as extensions of its London Innovation Center, to work with academics and entrepreneurs throughout the U.K. to identify early stage innovation and support the translation of research into new products for patients.

More... »

AstraZeneca donates Brixham Environmental Laboratory to Plymouth University

Monday, December 9, 2013 12:25 PM

AstraZeneca will donate its Environmental Laboratory in Brixham to Plymouth University to ensure the lab continues to serve scientific and research purposes.

More... »

NIHR Clinical Research Network improves non-commercial study inclusion times

Monday, December 9, 2013 12:22 PM

The National Institute for Health Research (NIHR) Clinical Research Network has decreased the time it takes for studies funded by non-commercial organizations, such as charitable organizations and academic institutions, to be included in the NIHR Portfolio of research.

More... »

The Medicines Company acquires Rempex Pharmaceuticals

Friday, December 6, 2013 01:04 PM

The Medicines Company has acquired Rempex Pharmaceuticals, a company with multiple potential new therapies focused on multi-drug resistant gram-negative bacteria.

More... »

Link to survey



Browse by:


December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs